Clinical characteristics of the MPN patients at diagnosis
| Diagnosis . | PV . | ET . | PMF . |
|---|---|---|---|
| Number of patients | 94 | 69 | 34 |
| % female | 51 | 67 | 26 |
| Average age at diagnosis (range), y | 58 (18-87) | 51 (21-86) | 61 (21-86) |
| Average time of follow-up, mo | 92 | 56 | 49 |
| Hemoglobin (g/L) average (range) | 181 (148-225) | 141 (78-225) | 126 (90-161) |
| Platelets (109/L) average (range) | 554 (90-1487) | 994 (452-1983) | 635 (16-1677) |
| Leukocytes (109/L) average (range) | 12 (4-39) | 9 (5-17) | 11 (5-27) |
| Neutrophils (109/L) average (range) | 9 (2-36) | 6 (3-16) | 8 (3-21) |
| Transformation to secondary myelofibrosis | 4 (4%) | 1 (1%) | NA |
| Transformation to AML | 3 (3%) | 2 (3%) | 2 (6%) |
| Diagnosis . | PV . | ET . | PMF . |
|---|---|---|---|
| Number of patients | 94 | 69 | 34 |
| % female | 51 | 67 | 26 |
| Average age at diagnosis (range), y | 58 (18-87) | 51 (21-86) | 61 (21-86) |
| Average time of follow-up, mo | 92 | 56 | 49 |
| Hemoglobin (g/L) average (range) | 181 (148-225) | 141 (78-225) | 126 (90-161) |
| Platelets (109/L) average (range) | 554 (90-1487) | 994 (452-1983) | 635 (16-1677) |
| Leukocytes (109/L) average (range) | 12 (4-39) | 9 (5-17) | 11 (5-27) |
| Neutrophils (109/L) average (range) | 9 (2-36) | 6 (3-16) | 8 (3-21) |
| Transformation to secondary myelofibrosis | 4 (4%) | 1 (1%) | NA |
| Transformation to AML | 3 (3%) | 2 (3%) | 2 (6%) |
NA, not applicable.